Innate Pharma S.A. (EPA: IPH)

Market Cap	155.75M
Revenue (ttm)	33.79M
Net Income (ttm)	-34.05M
Shares Out	80.95M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	5.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,269
Open	1.920
Previous Close	1.976
Day's Range	1.906 - 2.085
52-Week Range	1.332 - 2.800
Beta	0.79
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 27, 2025

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 179
• Stock Exchange: Euronext Paris
• Ticker Symbol: IPH

Financial Performance

In 2023, Innate Pharma's revenue was 61.64 million, an increase of 6.88% compared to the previous year's 57.67 million. Losses were -7.57 million, -86.97% less than in 2022.